Aranesp®

Generic Name: darbepoetin alfa
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20000219Anemia of cancer2

A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin alfa on Hospital Days, Economic Outcomes, and Health-related  Quality of Life in Subjects with Nonmyeloid Malignancies and Anemia of Cancer

20010103anemia of cancer3Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy
20010145Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC)3

A Randomizd Double Blind, Placebo-Controlled Study of Subject With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum plus Etoposide Chemotherapy with or without darbepoetin alfa

20010184Treatment of anemia in subjects with chronic kidney3

Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT)

20020149Treatment of anemia of cancer in subjects who are not receiving chemotherapy3A Multicenter, Double-blind, Placebo-controlled Roll over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer
20040104Treatment of anemia in patients with chronic kidney disease (CKD)3Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients with Chronic Kidney Disease Receiving Hemodialysis
20040156Chemotherapy Induced Anemia3bA Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy
20040218Treatment of anaemia in patients with Chronic Kidney Disease (CKD) receiving haemodialysis (HD).3bStudy to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving Haemodialysis
20050122Anaemia in elderly subjects with chronic kidney (CKD)3b

A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the SF-36 Vitality Score by Correcting Anaemia of Chronic Kidney Disease with Aranesp® (darbepoetin alfa) in the Elderly (STIMULATE) 

20050210Treatment of anemia in KCD subjects receiving dialisis3A multicenter, single-arm study evaluating the extension from weekly to once every other week darbepoetin alfa administration in subjects with chronic kidney disease receiving dialysis
20050222Subjects with heart failure who have symptomatic left3

A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of darbepoetin alfa treatment on mortality and morbidity in heart failure (HF) subjects with symptomatic left ventricular systolic dysfunction and anemia

20050239Chronic kidney disease and anemia4

A Prospective Observational Study to Evaluate Physical Performance and Quality of Life in Older Long Stay Nursing Home Residents with Chronic Kidney Disease with and without Anemia

20050256Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis3

Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis

20060103Anemia with Darbepoetin alfa with Iron in Subjects2

Once per Cycle Treatment of Anemia With Darbepoetin alfa With Iron in Subjects With Non-myeloid Malignancies

20060163Treatment of anemia in subjects with chronic kidney3

A Multicenter, Randomized, Double-blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis

20101123Symptomatic Chemotherapy-induced Anemia4

Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anemia: An International Prospective Observational Study (eAQUA)